• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Gastrointestinal
  • A Phase I, Open-label, Randomized, Single-center, 2-way Crossover Bioequivalence Study Comparing a Pellets Based Sachet Formulation of D961H 20 mg and a Commercial HPMC Capsule of D961H 20 mg After Repeated Oral Administration in Japanese Healthy Male Subjects.

Disease
bioequivalence
Drug Name
esomeprazole
Generic Name
esomeprazole
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
I
Start Date
May 14, 2012
Study Name
D961TC00001
Study Id
D961TC00001
ClinicalTrials.gov ID

NCT01595425

Recruiting Status
Closed
Protocol Status
Not Available
Report
Nov 2, 2012
  • D961TC00001.pdf (236 KB)

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013